R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl [be] substituted by alkoxy or one or more halo.

Page 4, third paragraph (lines 11-18), to page 5, first paragraph (lines 1-4):

In an embodiment represented by Formula I, the invention relates to:

$$H_3C$$
 H_3C
 R^3
 CO_2H
 R^2
 R^2

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl [be] substituted by alkoxy or one or more halo.

Page 5, fourth paragraph (lines 12-23):

In an embodiment represented by Formula III, the invention relates to:

$$H_3C$$
 H_3C
 R^3
 CO_2H

Ш

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl [be] substituted by alkoxy or one or more halo.

Page 6, second paragraph (lines 7-17):

In an embodiment represented by Formula V, the invention relates to:

$$H_3C$$
 H_3C
 R^3
 CO_2H
 R^2

٧

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl [be] substituted by alkoxy or one or more halo.

Page 17, last paragraph (line 30), to page 18, first paragraph (lines 1-10):

In an embodiment represented by Formula I, the invention relates to:

$$H_3C$$
 H_3C
 R^3
 CO_2H
 R^2
 R^2
 R^2
 R^2
 R^2

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl [be] substituted by alkoxy or one or more halo.

Page 21, ninth paragraph (lines 19-27), to page 22, first paragraph (lines 1-3):

In an embodiment represented by Formula III, the invention relates to:

$$H_3C$$
 H_3C
 R^3
 CO_2H

III

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl [be] substituted by alkoxy or one or more halo.

Page 25, fourth paragraph (lines 7-18):

In an embodiment represented by Formula V, the invention relates to:

$$H_3C$$
 NH
 R^3
 NH_2
 CO_2H

V

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl [be] substituted by alkoxy or one or more halo.

Page 44, lines 18-20, please delete (replace):

Example 1e):

[:]

Methyl (3E)-2-[(tert-butoxycarbonyl)amino]-5-cyano-2-methylpent-3-enoate